Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

7.86USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$7.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
228,538
52-wk High
$17.96
52-wk Low
$7.82

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $1,239.53
Shares Outstanding(Mil.): 105.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

05 Dec 2017

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

08 Nov 2017

BRIEF-Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211

* Lexicon Pharmaceuticals initiates patient dosing in a phase 1 study of LX9211 Source text for Eikon: Further company coverage:

27 Sep 2017

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

19 Sep 2017

BRIEF-Lexicon Pharma reports positive pooled continuous glucose monitoring data

* Lexicon Pharmaceuticals reports positive pooled continuous glucose monitoring data from pivotal phase 3 intandem1 and intandem2 studies of sotagliflozin

08 Sep 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
Roche Holding Ltd. (ROG.S) CHF221.90 -1.25
Roche Holding Ltd. (RO.S) CHF225.60 -0.40
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Bayer AG (BAYGn.DE) €98.03 +0.25
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.30 0.00
Eli Lilly and Co (LLY.N) $78.97 +0.95
Abbott Laboratories (ABT.N) $60.17 +0.67
Bristol-Myers Squibb Co (BMY.N) $68.96 -0.02

Earnings vs. Estimates